EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor-associated macrophage reprogramming in cancer: recent advances in resistance mechanisms and therapy

Abdullah Farhan Saeed, Muhammad Naim Ashraf, Muhammad Zaheer Iqbal

Frontiers in Immunology · 2026

DOI: 10.3389/fimmu.2026.1920004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Abdullah Farhan Saeed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Neoplasms, Cellular Reprogramming, Drug Resistance, Neoplasm. Die Arbeit nennt 330 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-associated macrophages (TAMs) are abundant, heterogeneous, and spatially organized immune cells that regulate cancer progression, immune evasion, metastasis, and therapeutic resistance. Single-cell and spatial technologies have revealed diverse TAM states shaped by ontogeny, tumor type, disease stage, cytokines, hypoxia, metabolism, epigenetic remodeling, extracellular matrix architecture, stromal interactions, extracellular vesicles, microbiome-derived signals, and therapy-induced damage. Bidirectional cancer-TAM crosstalk evolves from tumor initiation through progression and recurrence, generating tumor-specific resistance programs that suppress lymphocytes, impair antigen presentation and phagocytosis, promote angiogenesis and metabolic restriction, remodel stroma, mediate tolerogenic efferocytosis, and sustain stem-cell, metastatic, dormancy, and regenerative niches. Therapeutic strategies include blocking macrophage recruitment or survival, activating CD40/TLR/STING signaling, targeting PI3Kγ and STAT pathways, restoring phagocytosis, modulating efferocytosis, and applying metabolic, epigenetic, stromal, vascular, nanoparticle, RNA-based, microbiome-directed, and engineered-macrophage approaches. Randomized trials have established the efficacy of CSF1R inhibition in selected CSF1-driven, macrophage-dependent tumors, whereas most other TAM- or myeloid-directed strategies in conventional solid tumors have demonstrated only preliminary clinical activity or pharmacodynamic modulation without consistent durable benefit. Off-target toxicity, spatial heterogeneity, dynamic plasticity, preclinical-clinical discordance, and combination-treatment optimization remain major barriers. Biomarker-guided patient selection, longitudinal monitoring, tumor-specific targeting, and rationally sequenced combinations will be essential for converting tumor-supportive TAMs into durable antitumor effectors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor-Associated MacrophagesNeoplasmsCellular ReprogrammingDrug Resistance, NeoplasmHumansAnimalsTumor MicroenvironmentSignal TransductionEfferocytosis

Stichwörter der Autor:innen

TAM reprogrammingimmune checkpoint blockademacrophage plasticitymyeloid immunotherapytherapy resistancetumor microenvironmenttumor-associated macrophages

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
  • Department of Pathology, University of Lahore, Lahore, Punjab, Pakistan.
  • Department of Biological Sciences, Superior University, Lahore, Punjab, Pakistan.

Zitieren

APA

Saeed, A. F., Ashraf, M. N., & Iqbal, M. Z. (2026). Tumor-associated macrophage reprogramming in cancer: recent advances in resistance mechanisms and therapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1920004

Vancouver

Saeed AF, Ashraf MN, Iqbal MZ. Tumor-associated macrophage reprogramming in cancer: recent advances in resistance mechanisms and therapy. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1920004

BibTeX
@article{Saeed2026,
  author = {Saeed, Abdullah Farhan and Ashraf, Muhammad Naim and Iqbal, Muhammad Zaheer},
  title = {Tumor-associated macrophage reprogramming in cancer: recent advances in resistance mechanisms and therapy},
  journal = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1920004}
}
Kostenlos starten →